Consultation Launched to Ensure Long-term Access to CE-Marked Devices
The Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a significant consultation focused on the indefinite recognition of CE-marked medical devices in Great Britain. This move comes as part of efforts to enhance patient access and availability of essential medical technologies. As it stands, approximately 90% of medical devices used in Britain proudly carry the CE mark, an important certification that signifies conformity with European health and safety standards.
Chief Executive Lawrence Tallon emphasized that the medical technology (MedTech) industry has consistently called for long-term certainty regarding CE recognition. "Ensuring British patients can access the latest European-approved medical devices is critical. At the same time, reducing the bureaucratic burden on producers is essential for the growth of the MedTech sector," he said.
Key Proposals Highlighted in the Consultation
The consultation outlines several proposals, including:
- Extending the current transitional arrangements for devices certified under the EU Medical Device Directive (MDD) to align with the EU's transition to the Medical Device Regulation (MDR) timelines.
- Establishing indefinite recognition for devices that comply with both EU MDR and In Vitro Diagnostic Medical Devices Regulation (IVDR), facilitating easier market access.
- Introducing an international reliance route for higher-risk CE-marked devices while maintaining robust regulatory oversight.
These proposals aim to assure that vital medical devices remain consistently available, all while aligning the UK with broader governmental strategies for the life sciences sector, which aspires to cement its position as a leader in MedTech innovation by 2030.
Importance of Feedback from the Industry
The MHRA has opened this consultation to monitor and integrate insights from a diverse group of stakeholders, including healthcare professionals, device manufacturers, and patient advocacy groups. Their feedback is expected to shape the framework within which these devices will operate moving forward, reinforcing the regulatory policies that protect patient safety while fostering market access and innovation.
This consultation is particularly crucial considering the recent advancements in technology, such as artificial intelligence (AI) applications in medical devices, making it imperative for regulations to adapt accordingly to the rapidly evolving healthcare landscape.
The Path Forward for Regulatory Reform
Lawrence Tallon has noted that these measures align with the UK's aspirations detailed in the Life Sciences Sector Plan. The ability to recognize CE-marked devices indefinitely not only supports innovation but also enhances the UK's capability to respond to clinical needs more swiftly.
The consultation is open from February 16 to April 10, 2026. Given its far-reaching implications, all involved parties in the healthcare ecosystem are encouraged to partake and share their experiences and concerns.
The MHRA's ongoing commitment not only reflects a responsive regulatory framework but also highlights the importance of maintaining high standards in patient safety as the market evolves.
Add Row
Add
Write A Comment